Study guide
12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes
Key Takeaways Explain This Topic AI
Diffuse Large B-Cell Lymphoma (DLBCL) is categorized by Cell-of-Origin (GCB vs. ABC/non-GCB via Hans algorithm) and molecular rearrangements (Double-Hit/Triple-Hit HGBL harboring MYC and BCL2/BCL6 translocations, requiring dose-adjusted EPOCH-R instead of R-CHOP).
Pola-R-CHP (Polatuzumab vedotin + Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; POLARIX trial) establishes a new frontline standard in intermediate-to-high-risk DLBCL (IPI 2–5), achieving superior 2-year PFS (76.7% vs. 70.2%, HR 0.73) over R-CHOP by replacing neurotoxic vincristine with the anti-CD79b antibody-drug conjugate.
Relapsed/refractory aggressive B-cell lymphomas with early relapse (<12 months) or primary refractory disease are preferentially treated with autologous anti-CD19 CAR T-cell therapy (Axicabtagene ciloleucel per ZUMA-7 or Lisocabtagene maraleucel per TRANSFORM), which demonstrated significant event-free and overall survival superiority over traditional salvage chemotherapy plus auto-HCT.
Follicular lymphoma frontline management stratifies by GELF criteria: asymptomatic low tumor burden warrants watchful waiting, whereas high tumor burden warrants chemoimmunotherapy (Obinutuzumab/Rituximab + Bendamustine, CHOP, or CVP) or lenalidomide + rituximab (R-squared); bendamustine mandates mandatory PJP (Bactrim) and HSV/VZV (acyclovir) prophylaxis due to profound and prolonged CD4+ T-cell lymphopenia.
Mantle Cell Lymphoma (MCL) pathognomonically harbors t(11;14) CCND1 overexpression; fit patients receive high-dose cytarabine induction, auto-HCT consolidation, and maintenance rituximab (LyMa trial), while covalent (acalabrutinib, zanubrutinib) and non-covalent (pirtobrutinib) BTK inhibitors are preferred in relapsed disease and TP53-mutated disease.
Last updated: August 2026
12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes
Non-Hodgkin Lymphomas (NHL) represent a heterogeneous group of lymphoproliferative malignancies arising predominantly from B-lymphocytes (~85–90%), T-lymphocytes (~10–15%), or natural killer (NK) cells. Systemic therapeutic management is dictated by histologic grade (aggressive vs. indolent), cell-of-origin (COO), cytogenetic translocations (e.g., MYC , BCL2 , BCL6 , CCND1 ), the International Prognostic Index (IPI), and patient-specific fitness.
Board-certified oncology pharmacists must navigate complex molecular diagnostics, calculate specialized dose-adjusted protocols (e.g., DA-EPOCH-R), intercept severe drug interactions with targeted kinase inhibitors, manage bispecific T-cell engager step-up dosing to prevent cytokine release syndrome (CRS), and institute comprehensive antimicrobial prophylaxis regimens.
1. Diffuse Large B-Cell Lymphoma (DLBCL) & Aggressive B-Cell Lymphomas
DLBCL is the most common lymphoid malignancy in adults, accounting for ~30–35% of newly diagnosed NHL cases.
Cell of Origin & Molecular Classification
Cell of Origin (COO): Gene expression profiling segregates DLBCL into Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC / Non-GCB) subtypes. In clinical practice, the Hans Immunohistochemistry Algorithm serves as the validated surrogate: +---------------------------------------------------------------------------------------------------+
- | HANS IMMUNOHISTOCHEMICAL ALGORITHM FOR DLBCL |
- | |
- | [CD10 Expression] |
- | | |
- | +------------------------+------------------------+ |
- | | (Positive >=30%) | (Negative <30%) |
- | v v |
- | [GCB SUBTYPE] [BCL6 Expression] |
- | | |
- | +------------------------+-------------------+ |
- | | (Negative <30%) (Positive >=30%)| |
- | v v |
- | [NON-GCB / ABC] [MUM1 Expr] |
- | | |
- | +-----------------------+---+ |
- | | (<30%) (>=30%) | |
- | v v |
- | [GCB SUBTYPE] [NON-GCB] |
- +---------------------------------------------------------------------------------------------------+
High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements ("Double-Hit" / "Triple-Hit" Lymphoma): Defined by cytogenetic translocations detected via fluorescence in situ hybridization (FISH). These carry an exceptionally poor prognosis with standard R-CHOP (2-year PFS <40%) and mandate intensive frontline therapy with Dose-Adjusted EPOCH-R .
Double-Expressor Lymphoma (DEL): Defined by protein overexpression on IHC ( MYC >=40% and BCL2 >=50% ) without underlying gene rearrangements on FISH. DEL is treated with standard frontline chemoimmunotherapy (Pola-R-CHP or R-CHOP).
International Prognostic Index (IPI) Scoring
One point is assigned for each risk factor ( APLES ):
- A ge > 60 years
- P erformance status (ECOG >= 2)
- L DH > upper limit of normal
- E xtranodal sites >= 2
- S tage III or IV
Risk Strata: Low (0–1), Low-Intermediate (2), High-Intermediate (3), High (4–5).
Frontline Systemic Therapy Protocols +---------------------------------------------------------------------------------------------------+
- | FRONTLINE DLBCL REGIMEN SELECTION: Pola-R-CHP vs R-CHOP |
- | |
- | [POLARIX TRIAL: Pola-R-CHP] (Tilly et al. NEJM 2022) |
- | - Target: IPI 2 to 5 (Intermediate-to-High Risk DLBCL) |
- | - Polatuzumab vedotin: 1.8 mg/kg IV Day 1 (Anti-CD79b ADC with MMAE payload) |
- | - Rituximab: 375 mg/m2 IV Day 1 |
- | - Cyclophosphamide: 750 mg/m2 IV Day 1 |
- | - Doxorubicin: 50 mg/m2 IV Day 1 |
- | - Prednisone: 100 mg PO daily Days 1 to 5 |
- | - (VINCRISTINE IS REMOVED AND REPLACED BY POLATUZUMAB VEDOTIN) |
- | - Cycle: Every 21 days x 6 cycles (plus 2 additional doses of single-agent Rituximab) |
- | - Efficacy: 2-year PFS **76.7% vs. 70.2%** (HR 0.73, p = 0.02); OS similar at 2 years |
- | - Subgroup Benefit: Most pronounced in ABC/Non-GCB subtype and IPI 3-5 |
- | |
- | [STANDARD R-CHOP-21] |
- | - Target: IPI 0 to 1 (Low Risk) or select GCB subtype |
- | - Rituximab 375 mg/m2 + Cyclophosphamide 750 mg/m2 + Doxorubicin 50 mg/m2 + |
- | Vincristine 1.4 mg/m2 (CAPPED AT 2.0 mg) Day 1 + Prednisone 100 mg PO D1-5 Q21D x 6 cycles |
- +---------------------------------------------------------------------------------------------------+
- Dose-Adjusted EPOCH-R (DA-EPOCH-R) Pharmacist Dosing Algorithm
Used in Double-Hit/Triple-Hit HGBL, Primary Mediastinal B-Cell Lymphoma (PMBCL), and Burkitt Lymphoma. Administered as a 96-hour continuous IV infusion:
- Etoposide: 50 mg/m2/day continuous IV infusion over 96 hours (Days 1–4; total 200 mg/m2)
- Doxorubicin: 10 mg/m2/day continuous IV infusion over 96 hours (Days 1–4; total 40 mg/m2)
Vincristine: 0.4 mg/m2/day continuous IV infusion over 96 hours (Days 1–4; total 1.6 mg/m2— NO 2 mg DOSE CAP! )
- Cyclophosphamide: 750 mg/m2 IV on Day 5
- Prednisone: 60 mg/m2 PO BID on Days 1–5
- Rituximab: 375 mg/m2 IV on Day 1
Pharmacist Dose Titration Rules: Adjust Etoposide, Doxorubicin, and Cyclophosphamide for subsequent cycles based on the nadir ANC and platelet count from twice-weekly CBCs:
If nadir ANC >= 500/mcL on all measurements: Increase doses of Etoposide, Doxorubicin, and Cyclophosphamide by 20% .
If nadir ANC < 500/mcL on 1 or 2 measurements: Maintain same dose.
If nadir ANC < 500/mcL for >= 3 measurements OR nadir Platelets < 25,000/mcL: Decrease doses by 20% .
Central Nervous System (CNS) Prophylaxis in DLBCL
Patients with high risk of CNS relapse (CNS-IPI score >=4, involvement of kidney, adrenal glands, testes, bone marrow, or Double-Hit status) mandate CNS prophylaxis:
Preferred: High-Dose Methotrexate ( HD-MTX >=3.0–3.5 g/m2 IV ) with aggressive hyperhydration (urine output >100 mL/h), urinary alkalinization ( urine pH >=7.5 with sodium bicarbonate), and leucovorin rescue , administered intercalated on Day 15 of chemoimmunotherapy cycles or after completion of systemic therapy.
Alternative: Intrathecal methotrexate (12 mg) and/or cytarabine (50 mg).
2. Relapsed & Refractory DLBCL: CAR T-Cell & Bispecific Therapeutics +---------------------------------------------------------------------------------------------------+
- | SECOND-LINE & LATER RELAPSED / REFRACTORY DLBCL ALGORITHM |
- | |
- | PRIMARY REFRACTORY OR EARLY RELAPSE (<12 MONTHS FROM COMPLETION OF CHEMOIMMUNOTHERAPY) |
- | | |
- | v |
- | [AUTOLOGOUS ANTI-CD19 CAR T-CELL THERAPY] (Category 1 Preferred Standard) |
- | - **Axicabtagene ciloleucel (Axi-cel)** (ZUMA-7: 2-yr EFS 40.5% vs 16.3%, OS HR 0.73) OR |
- | - **Lisocabtagene maraleucel (Liso-cel)** (TRANSFORM: EFS 10.1 vs 2.3 mo, HR 0.35) |
- | - SUPERIOR TO PLATINUM SALVAGE (R-ICE/R-DHAP) + AUTO-HCT! |
- | |
- | LATE RELAPSE (>=12 MONTHS) & TRANSPLANT-ELIGIBLE |
- | | |
- | v |
- | [PLATINUM SALVAGE CHEMOTHERAPY] -> If Chemoresponsive (CMR/PMR) -> [HIGH-DOSE CHEMO + AUTO-HCT]|
- | - Regimens: R-ICE, R-DHAP, or R-GDP |
- | |
- | THIRD-LINE OR POST-CAR T / TRANSPLANT-INELIGIBLE RELAPSE |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v v |
- | [CD20 x CD3 BISPECIFIC ANTIBODIES] [ANTIBODY-DRUG CONJUGATES / TARGETED] |
- | - **Epcoritamab** (EPCORE NHL-1; Subcutaneous; - **Loncastuximab tesirine** (LOTIS-2; |
- | Step-up dosing D1, D8, D15) Anti-CD19 ADC with PBD alkylator payload) |
- | - **Glofitamab** (NP30179; IV; 2:1 CD20:CD3; - **Tafasitamab + Lenalidomide** (L-MIND; |
- | Obinutuzumab pretreatment, 12 fixed cycles) Anti-CD19 mAb + immunomodulatory agent) |
- +---------------------------------------------------------------------------------------------------+
- CD20 x CD3 Bispecific T-Cell Engagers (BsAbs) in DLBCL
Agent Format & Target Dosing Schedule & Step-Up Administration Key Efficacy Data Toxicity Interception & Pharmacist Mandates
Epcoritamab Subcutaneous; 1:1 Bispecific IgG4 (CD20 x CD3) Cycle 1 Step-Up Dosing: ; Day 1: 0.16 mg SC; Day 8: 0.8 mg SC; Day 15: 48 mg SC (full dose); Day 22: 48 mg SC; Cycles 2–3: Weekly 48 mg; Cycles 4–9: Q2W; Cycles >=10: Q4W EPCORE NHL-1 (Thieblemont et al. Lancet 2023). Relapsed/refractory DLBCL post-CAR T or >=2 prior lines: ORR 63%, CR rate 39% , median DOR 12 months. Cytokine Release Syndrome (CRS in 50%, mostly Grade 1–2). Mandatory hospitalization for 24h after C1D15 dose. Premedicate with dexamethasone, diphenhydramine, and acetaminophen. ICANS in 6%.
Glofitamab Intravenous; 2:1 Bispecific (Two CD20 binding domains to One CD3 domain) Pre-treatment: Obinutuzumab 1,000 mg IV on C1D1 (depletes peripheral B-cells to reduce CRS).; Cycle 1 Step-Up: ; Day 8: 2.5 mg IV; Day 15: 10 mg IV; Cycle 2 Day 1: 30 mg IV (target dose) Q21D for 12 fixed cycles total NP30179 Trial (Dickinson et al. NEJM 2022). Heavily pretreated DLBCL (33% prior CAR T): ORR 52%, CR rate 39% , 12-month complete response durability 78%. Fixed-duration therapy (35 weeks). CRS in 63% (Grade 3–4 in 4%). Premedicate with IV dexamethasone 20 mg. Monitor tocilizumab availability on site prior to infusion.
- 3. Indolent B-Cell Lymphomas: Follicular & Marginal Zone Lymphomas
- Follicular Lymphoma (FL)
Follicular lymphoma is the second most common NHL (~20–25%), characterized by the pathognomonic chromosomal translocation t(14;18)(q32;q21) , which places the BCL2 proto-oncogene under the control of the immunoglobulin heavy chain ( IGH ) promoter, causing constitutive BCL-2 overexpression and inhibition of apoptosis.
Histologic Grading: Grade 1 (0–5 centroblasts/HPF), Grade 2 (6–15 centroblasts/HPF), Grade 3A (>15 centroblasts with centrocytes present), Grade 3B (sheets of centroblasts without centrocytes). Grade 3B is treated aggressively as DLBCL! (R-CHOP / Pola-R-CHP).
Indications for Treatment (GELF Criteria):
- Involvement of >=3 nodal sites, each with diameter >=3 cm
- Any single nodal or extranodal mass >=7 cm
- Symptomatic splenomegaly
- Organ compression / risk of vital organ compromise
- Ascites or pleural effusion
- Cytopenias (ANC <1,000/mcL or Platelets <100,000/mcL)
- Systemic B symptoms
Asymptomatic low tumor burden patients are managed with Watchful Waiting (observation) . +---------------------------------------------------------------------------------------------------+
- | FRONTLINE HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA MATRIX |
- | |
- | [BENDAMUSTINE + OBINUTUZUMAB (G-Benda) or RITUXIMAB (BR)] |
- | - **Bendamustine:** 90 mg/m2 IV Days 1 and 2 Q28D x 6 cycles |
- | - **Obinutuzumab:** 1,000 mg IV C1D1, D8, D15; then Day 1 of Cycles 2-6 (GALLIUM trial) OR |
- | - **Rituximab:** 375 mg/m2 IV Day 1 Q28D x 6 cycles (StiL / BRIGHT trials) |
- | - Efficacy: G-chemo improves PFS over R-chemo (7-yr PFS 63% vs 55%; HR 0.77, p=0.006) |
- | - Maintenance: Obinutuzumab or Rituximab 1,000 mg/375 mg/m2 Q2M x 2 years |
- | - PHARMACIST MANDATE: **Mandatory PJP prophylaxis (TMP-SMX) and VZV/HSV prophylaxis |
- | (Acyclovir/Valacyclovir)** throughout therapy and for >=6-12 months post-bendamustine due |
- | to profound, prolonged CD4+ T-cell depletion (CD4 nadir often <200/mcL)! |
- | |
- | [R-CHOP / G-CHOP] or [R-CVP / G-CVP] |
- | - Preferred when high risk of histologic transformation to DLBCL is suspected |
- | - Followed by 2 years of maintenance CD20 antibody in responders |
- | |
- | [R-SQUARED (R2) REGIMEN: RELEVANCE & AUGMENT TRIALS] |
- | - **Lenalidomide:** 20 mg PO daily Days 1 to 21 Q28D x 6 to 12 cycles |
- | - **Rituximab:** 375 mg/m2 IV weekly x 4 doses (Cycle 1), then Day 1 of Cycles 2 to 5 |
- | - Non-cytotoxic chemo-free option; mandatory antithrombotic prophylaxis (Aspirin 81 mg daily) |
- +---------------------------------------------------------------------------------------------------+
- Relapsed/Refractory Follicular Lymphoma Targeted Agents
Mosunetuzumab: Full CD20 x CD3 bispecific antibody with step-up dosing (Day 1: 1 mg, Day 8: 2 mg, Day 15: 60 mg, Cycle 2 Day 1: 60 mg, Cycle 3+ Day 1: 30 mg Q21D for 8–17 cycles). Established 80% ORR and 60% CR rate in heavily pretreated FL.
Zanubrutinib + Obinutuzumab: ROSEWOOD trial demonstrated PFS superiority over obinutuzumab monotherapy in relapsed/refractory FL.
Tazemetostat: Oral EZH2 methyltransferase inhibitor (800 mg PO BID) indicated for relapsed/refractory FL harboring EZH2 gain-of-function mutations (or wild-type with no alternative therapies).
4. Mantle Cell Lymphoma (MCL)
MCL represents ~5–7% of NHL cases, characterized by the hallmark translocation t(11;14)(q13;q32) , which fuses the CCND1 gene to the IGH enhancer, resulting in overexpression of Cyclin D1 and cell cycle progression from G1 to S phase. It is universally positive for SOX11 and CD5+ / CD19+ / CD20+ / CD23-. +---------------------------------------------------------------------------------------------------+
- | MANTLE CELL LYMPHOMA (MCL) TREATMENT PARADIGM |
- | |
- | [YOUNG / FIT / TRANSPLANT-ELIGIBLE MCL] |
- | - Induction: High-dose Cytarabine-containing chemoimmunotherapy (MANDATORY): |
- | * Alternating R-CHOP / R-DHAP (LyMa trial) OR Nordic Regimen (Maxi-CHOP / High-dose Ara-C) |
- | * HyperCVAD + Rituximab alternating with HD-MTX/Cytarabine |
- | - Consolidation: High-Dose Chemotherapy (BEAM) + **Autologous Stem Cell Transplantation** |
- | - Maintenance: **Maintenance Rituximab 375 mg/m2 IV every 2 months for 3 YEARS** |
- | * LyMa Trial (Hermine et al. NEJM 2017): 4-yr EFS 79% vs 61%; **4-yr OS 89% vs 80% (HR 0.50)**|
- | |
- | [ELDERLY / TRANSPLANT-INELIGIBLE MCL] |
- | - Induction: Bendamustine + Rituximab (BR) x 6 cycles OR VR-CAP (Bortezomib substituted for VCR)|
- | - Maintenance: Maintenance Rituximab every 2 months for 2 years (or until progression) |
- | |
- | [TP53-MUTATED MCL (10-15% of cases)] |
- | - Chemoresistant phenotype with poor median OS (<2-3 years) with traditional chemo-HCT |
- | - Prioritize BTK inhibitor + Venetoclax clinical trials or frontline BTK inhibitor combinations |
- | |
- | [RELAPSED / REFRACTORY MCL THERAPEUTICS] |
- | - Second-Generation Covalent BTK Inhibitors (Preferred over Ibrutinib due to lower AF/bleeding):|
- | * **Acalabrutinib:** 100 mg PO BID (Avoid PPIs; take 2h before H2RAs/antacids) |
- | * **Zanubrutinib:** 160 mg PO BID or 320 mg PO daily (No gastric pH interaction) |
- | - Non-Covalent (Reversible) BTK Inhibitor: |
- | * **Pirtobrutinib:** 200 mg PO daily (BRUIN trial; retains potency against C481S mutations!) |
- | - CAR T-Cell Therapy: **Brexucabtagene autoleucel (Tecartus)** post-BTK progression (ZUMA-2) |
- +---------------------------------------------------------------------------------------------------+
- 5. T-Cell & Cutaneous Lymphomas
T-cell lymphomas represent aggressive, biologically distinct neoplasms requiring specialized biomarker-directed therapy.
Peripheral T-Cell Lymphoma (PTCL)
CD30 Expression: Expressed in 100% of Anaplastic Large Cell Lymphoma (ALCL; ALK+ and ALK-) and variable subsets (15–50%) of PTCL-Not Otherwise Specified (PTCL-NOS) and Angioimmunoblastic T-Cell Lymphoma (AITL).
Frontline Standard (ECHELON-2 Trial; Pro et al. Lancet 2019):
BV-CHP: Brentuximab vedotin (1.8 mg/kg IV) + Cyclophosphamide (750 mg/m2) + Doxorubicin (50 mg/m2) + Prednisone (100 mg PO D1–5) Q21D x 6 cycles. ( Vincristine omitted ).
Efficacy: Significant PFS and OS improvement over CHOP ( 5-year OS 70.1% vs. 61.0%, HR 0.72 ).
Consolidate with Autologous HCT in first remission for fit patients with non-ALK+ ALCL, AITL, and PTCL-NOS.
Relapsed PTCL Agents: Pralatrexate (antifolate; mandatory pre-supplementation with Vitamin B12 1 mg IM Q8–10W and Folic Acid 1 mg PO daily to prevent lethal mucositis and myelosuppression), Romidepsin (HDAC inhibitor; baseline ECG/QTc monitoring), Belinostat.
Cutaneous T-Cell Lymphoma (CTCL: Mycosis Fungoides & Sézary Syndrome)
Mogamulizumab: Monoclonal antibody targeting CCR4 (chemokine receptor 4) with enhanced ADCC. Phase 3 MAVORIC trial demonstrated superior PFS over vorinostat, with dramatic clearance of the leukemic/blood compartment in Sézary syndrome. Toxicities: dermatologic rash (drug eruption vs disease flare; skin biopsy required), infusion reactions, risk of severe GVHD if subsequently undergoing allogeneic HCT.
Bexarotene: Oral retinoid X receptor (RXR) selective agonist (300 mg/m2 PO daily with a meal). Signature toxicities requiring proactive pharmacist co-prescription:
Severe Hypertriglyceridemia (>80%): Initiate prophylactic Fenofibrate (avoid gemfibrozil due to CYP2C8 interaction) or omega-3 fatty acids before starting.
Central Hypothyroidism (>90%): Suppresses pituitary TSH secretion; initiate prophylactic Levothyroxine (Synthroid 25–50 mcg daily) and monitor Free T4 (not TSH!).
Vorinostat: Oral histone deacetylase (HDAC) inhibitor (400 mg PO daily with food). Toxicities: fatigue, severe diarrhea, thromboembolism (DVT/PE in 5%), QTc prolongation.